



June 5, 2025

| | |
|-----------------|--|
| Company Name: | GNI Group Ltd. |
| Representative: | Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth) |
| Contact Person: | Director, Executive Officer, Vice President COO and CFO Ryosuke Matsui (TEL. 03-6214-3600) |

Announcement of the Launch of Etoel (Nintedanib Esilate Soft Capsules) by Gyre Pharmaceuticals

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. announces that its core subsidiary, Gyre Pharmaceuticals Co., Ltd., has commenced sales of "Etoel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement Entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals."

The successful launch of Etoel (Nintedanib Esilate Soft Capsules) for Gyre Pharmaceuticals Co., Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases.

The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilate Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD).

The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast.